U.S. Markets close in 2 hrs 44 mins
  • S&P 500

    4,295.00
    +14.85 (+0.35%)
     
  • Dow 30

    33,920.88
    +159.83 (+0.47%)
     
  • Nasdaq

    13,115.58
    +68.40 (+0.52%)
     
  • Russell 2000

    2,014.09
    -2.53 (-0.13%)
     
  • Crude Oil

    89.38
    -2.71 (-2.94%)
     
  • Gold

    1,798.60
    -16.90 (-0.93%)
     
  • Silver

    20.30
    -0.40 (-1.92%)
     
  • EUR/USD

    1.0174
    -0.0083 (-0.8139%)
     
  • 10-Yr Bond

    2.7860
    -0.0630 (-2.21%)
     
  • Vix

    20.02
    +0.49 (+2.51%)
     
  • GBP/USD

    1.2079
    -0.0059 (-0.4880%)
     
  • USD/JPY

    133.1960
    -0.2840 (-0.2128%)
     
  • BTC-USD

    24,245.75
    -6.44 (-0.03%)
     
  • CMC Crypto 200

    577.28
    -13.48 (-2.28%)
     
  • FTSE 100

    7,509.15
    +8.26 (+0.11%)
     
  • Nikkei 225

    28,871.78
    +324.80 (+1.14%)
     

Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

TORONTO, Ontario, July 28, 2022--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM" is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference being held at the InterContinental Boston Hotel on August 8-11, 2022.

Mr. Drysdale’s fireside chat will be webcast live on Thursday, August 11, 2022 at 3:30 p.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.

About Cybin

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220728005365/en/

Contacts

Investor & Media:
Leah Gibson
Vice President, Investor Relations & Strategic Communications
Cybin Inc.
irteam@cybin.com – or – media@cybin.com